Menu
Search Close

Using immunology to fight cancer

Read more

In Phase 1/2 clinical trials for the treatment of patients with metastatic melanoma

Read more

Novel vaccine platform that destroys tumours 

Read more

Cancer Immunotherapy

Cancer remains one of the world’s most significant diseases. A key challenge in the fight against cancer is that many tumours continue to grow by successfully evading the body’s own natural defence mechanism - the immune system. Scancell’s mission is to overcome this breach in our defences by developing products that stimulate the immune system to treat or prevent cancer.

The company, which was founded in 1997 as a spin-out from the University of Nottingham, has secured £23 million funding to date. In December 2006 Scancell sold its pipeline of direct killing monoclonal antibodies to Arana Therapeutics, an Australian biopharmaceutical company. The deal allowed Scancell to focus its efforts entirely on its innovative ImmunoBody® and Moditope® cancer vaccine programmes.

Read more

Presentation

Biotech and Money Inv€$tival Showcase - 14th November 2017

Aim logo

Scancell Holdings PLC is an AIM listed company

Webcasts, Interviews and Media Coverage

Scancell recruits deal maker to take over as CEO

Executive chairman John Chiplin said new CEO Dr Cliff Holloway's extensive experience and accomplishments speak volumes

Tue, 10 Oct 2017 08:24:00

Scancell on the lookout for partners after year of “significant progress”

“We are continuing to explore a number of funding options to ensure that we have the resources to progress these programmes through their next phase”

Wed, 13 Sep 2017 06:21:00

Scancell presents Moditope data at prestigious cancer conference

Chief scientific officer Lindy Durrant presented two posters at the International Cancer Immunotherapy conference in Germany on Friday

Mon, 11 Sep 2017 09:25:00